Stryker Co. (NYSE:SYK) Shares Bought by E Fund Management Co. Ltd.

E Fund Management Co. Ltd. raised its stake in Stryker Co. (NYSE:SYK) by 14.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 957 shares of the medical technology company’s stock after acquiring an additional 124 shares during the period. E Fund Management Co. Ltd.’s holdings in Stryker were worth $287,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of SYK. Magellan Asset Management Ltd boosted its stake in shares of Stryker by 74,911.8% during the third quarter. Magellan Asset Management Ltd now owns 680,357 shares of the medical technology company’s stock worth $185,921,000 after buying an additional 679,450 shares during the period. Barclays PLC boosted its stake in shares of Stryker by 103.5% during the third quarter. Barclays PLC now owns 1,084,987 shares of the medical technology company’s stock worth $296,493,000 after buying an additional 551,798 shares during the period. Morgan Stanley raised its holdings in Stryker by 4.4% during the third quarter. Morgan Stanley now owns 5,315,227 shares of the medical technology company’s stock worth $1,452,493,000 after purchasing an additional 223,728 shares in the last quarter. The Manufacturers Life Insurance Company raised its holdings in Stryker by 24.2% during the third quarter. The Manufacturers Life Insurance Company now owns 1,115,955 shares of the medical technology company’s stock worth $304,957,000 after purchasing an additional 217,672 shares in the last quarter. Finally, Ameriprise Financial Inc. raised its holdings in Stryker by 14.4% during the third quarter. Ameriprise Financial Inc. now owns 1,547,683 shares of the medical technology company’s stock worth $422,099,000 after purchasing an additional 194,715 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Buying and Selling at Stryker

In other Stryker news, CAO William E. Berry, Jr. sold 7,690 shares of Stryker stock in a transaction on Thursday, March 7th. The shares were sold at an average price of $358.48, for a total value of $2,756,711.20. Following the transaction, the chief accounting officer now owns 3,675 shares in the company, valued at approximately $1,317,414. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 5.50% of the stock is owned by company insiders.

Stryker Trading Up 0.5 %

NYSE SYK traded up $1.58 during mid-day trading on Thursday, reaching $330.86. 980,401 shares of the stock were exchanged, compared to its average volume of 1,327,501. Stryker Co. has a 1-year low of $249.98 and a 1-year high of $361.41. The business’s fifty day simple moving average is $345.60 and its 200 day simple moving average is $318.91. The stock has a market capitalization of $126.04 billion, a PE ratio of 37.77, a PEG ratio of 2.54 and a beta of 0.91. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.99 and a current ratio of 1.71.

Stryker (NYSE:SYK) last announced its earnings results on Tuesday, April 30th. The medical technology company reported $2.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.36 by $0.14. The firm had revenue of $5.24 billion for the quarter, compared to analyst estimates of $5.10 billion. Stryker had a net margin of 16.03% and a return on equity of 23.05%. Stryker’s revenue was up 9.7% compared to the same quarter last year. During the same quarter last year, the business earned $2.14 earnings per share. On average, research analysts anticipate that Stryker Co. will post 11.94 earnings per share for the current fiscal year.

Analyst Ratings Changes

SYK has been the subject of several analyst reports. StockNews.com raised shares of Stryker from a “hold” rating to a “buy” rating in a report on Tuesday, January 23rd. Roth Mkm increased their price target on shares of Stryker from $348.00 to $405.00 and gave the stock a “buy” rating in a report on Wednesday, May 1st. Evercore ISI increased their price target on shares of Stryker from $340.00 to $370.00 and gave the stock an “outperform” rating in a report on Thursday, April 4th. Royal Bank of Canada increased their price target on shares of Stryker from $360.00 to $386.00 and gave the stock an “outperform” rating in a report on Monday, April 15th. Finally, Canaccord Genuity Group raised shares of Stryker from a “hold” rating to a “buy” rating and increased their target price for the company from $315.00 to $360.00 in a report on Wednesday, January 31st. Four analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $365.94.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.